Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219450 · ClinicalTrials.gov registry record · Phase 1
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
A Phase 1 study of Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03219450: Recruiting Phase 1 study of Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT03219450 is a Phase 1 study of Lymphocytic Leukemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 15 participants, below the 25-participant average among 4 other Lymphocytic Leukemia trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03219450, a Phase 1 study of Lymphocytic Leukemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
Primary Outcome
The proportion of all enrolled patients for whom sequencing and analysis leads to identification of at least 7 actionable peptides to initiate vaccine production
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cyclophosphamide
- DRUG NeoVax
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-08-18 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
What NCT03219450 shows while recruiting
NCT03219450 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 25-participant average among 4 other Lymphocytic Leukemia trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03219450 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03219450 about?
NCT03219450 is a clinical study titled "A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.". This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
What is the current status of trial NCT03219450?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-08-18. Estimated completion is 2028-03-31.
What conditions does trial NCT03219450 study?
This clinical trial studies the following conditions: Lymphocytic Leukemia.
What interventions are being tested in trial NCT03219450?
The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), NeoVax (DRUG).
Who is sponsoring clinical trial NCT03219450?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03219450 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
COMPLETED · Phase 1
-
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
COMPLETED · Phase 1
-
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
COMPLETED · Early Phase 1
-
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI